Welcome

Sign out Have a question? We're here to help

Sign out

Aldeyra Therapeu (ALDX)

$2.12 0.00 (0.00%)

17:31 EDT ALDX Stock Quote Delayed 20 Minutes

Volume:

Previous Close $2.12

Market Cap 42.63M

PE Ratio -1.45

EPS -1.46

Volume (Avg. Vol.)

Day's Range 2.12 - 2.12

52-Week Range 1.48 - 9.05

Dividend & Yield N/A (N/A)

ALDX Stock Predictions, Articles, and Aldeyra Therapeu News

From InvestorPlace
From the Web

Aldeyra Therapeutics Stock Skyrockets on Dry Eye Study Results

By Karl Utermohlen, InvestorPlace Writer Sep 26, 2018

Aldeyra Therapeutics stock (ALDX) gained more than 60% on Wednesday as the company unveiled positive results of its dry eye disease drug.

5 Hot Insider Stock Picks You Need to Know

By Harriet Lefton, Writer, TipRanks Jul 18, 2017

Wondering what the insiders are currently snapping up? These 5 names are big insider stock picks right now.

Best & Worst Performing Small Cap Stocks for March 25, 2020

From StockNews.com Mar 25, 2020

MFA – MFA leads the way today as the best performing small cap stock, closing up 216.67%.

What Makes Aldeyra Therapeutics, Inc. (ALDX) a New Buy Stock

From Zacks Investment Research Mar 24, 2020

Aldeyra Therapeutics, Inc. (ALDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates

From Benzinga Mar 18, 2020

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 17) BioNTech SE – ADR...

Chair of the Board Richard Douglas Just Bought Shares In Aldeyra Therapeutics, Inc. (NASDAQ:ALDX)

From Simply Wall St Mar 18, 2020

Potential Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) shareholders may wish to note that the Chair of the Board, Richard Douglas, recently bought US$110k worth of stock, paying US$2.75 for each share. That’s<div><a class="permalink" href="https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-aldx/aldeyra-therapeutics/news/chair-of-the-board-richard-douglas-just-bought-shares-in-aldeyra-therapeutics-inc-nasdaqaldx/">Read More...</a></div>

Aldeyra Therapeutics (ALDX) Receives a Buy from JonesTrading

From Analyst Ratings Mar 12, 2020

JonesTrading analyst Matthew Cross reiterated a Buy rating on Aldeyra Therapeutics (ALDX – Research Report) today and set a price target of $34.00. The company’s shares closed last Monday at $2.59, close to its 52-week low of $2.50. According to TipRanks.com, Cross is a 1-star analyst with an average return of -2.1% and a 29.0%

The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO

From Benzinga Mar 12, 2020

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 11) Bicycle Therapeutics...

Navellier Ratings

Total Grade

Sell

Premium Services

We are always here to help!

Not Yet a Subscriber?

Welcome

Welcome

Breaking news

Aldeyra Therapeu (ALDX)

Navellier Ratings

Total Grade

Premium Services

We are always here to help!

Not Yet a Subscriber?

Welcome

Already a subscriber?

Welcome

Breaking news

Aldeyra Therapeu (ALDX)

ALDX Stock Predictions, Articles, and Aldeyra Therapeu News

Navellier Ratings

Total Grade

Subscriber Sign in